LU LUPIN
Lupin Q1 2027
LULUPIN

Lupin Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 7 Aug 2026

Management summary

  • Lupin reported a record Q1 FY27 with strong revenue and EBITDA growth.
  • Diversified performance across all key geographies and significant margin expansion..
  • While the US business saw robust sales, management anticipates moderation in the coming quarters due to increased competition in key products.
  • The company remains focused on complex and innovative product pipelines and maintaining high compliance standards.

Source: Inve concall analysis and management guidance record.

Highlights

  • Record quarter with total revenues from operations exceeding INR 8,000 crores and EBITDA exceeding INR 2,400 crores, respectively, for the first time in company history.

  • Achieved 16th consecutive quarter of YoY growth.

  • Ex-U.S. organic revenue growth was a strong 20%+ YoY, with double-digit growth in all key markets.

  • Gross Margins improved by 330 basis points YoY to 74.6% from 71.3% in Q1FY26.

What they filed

Q1 FY27: revenue up 25.6%, net profit up 27.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue4,208 4,486 5,709 4,068 4,501 +7%5,235 +17%7,172 +26%
EBITDA1,411 1,746 2,730 1,176 1,617 +15%2,282 +31%3,733 +37%
Net profit985 1,291 2,128 1,357 717 −27%2,164 +68%2,715 +28%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue Growth

  • Overall Revenue Growth Revenue Growth · FY27 · High confidence high single-digit

EBITDA Margins

  • Overall EBITDA Margins EBITDA Margins · FY27 · High confidence around 25%

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
US Sales Guidance Step-down Direct
In Q1, you don't have any additional competition on Tolvaptan. And from Q2 onwards, you will start seeing the impact of Apotex and Teva. We also expect in September, we could potentially have one more entrant. We expect to be a four-player market with Tolvaptan. And we expect the

Clarifies the reasons for the anticipated decline in US sales from Q1 levels, attributing it to new competition in key products like Tolvaptan and Mirabegron.

Asked by Shyam Srinivasan

Normalized Gross Margin Direct
It is really going to be a function of how much of Tolvaptan sales and at what realization, the kind of competition that you see out there. And more importantly, the impact of price increases that we have seen in the recent past; post the cost increase that is because of the geop

Explains why Q1's high gross margin is not sustainable for the full year, citing competition, geopolitical cost increases, and inventory effects.

Asked by Shyam Srinivasan

Unlock risks & concerns, Q2 FY27 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 7 risks, concerns & management red flags
  • 5 watchlist triggers for Q2 FY27
  • +17 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image